NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

Yes, that’s my read. In the past, NICE attempted to review all treatments within 90 days after licensing by the MHRA, but in order to speed access to patients, NICE is attempting to review and collaborate with the MHRA during the licensing assessment stage to have a decision as soon as a drug or treatment receives a license. This Parliament discussion reveals that due to bureaucracy and other issues, NICE is not actually working with the MHRA as intended, and the NICE review in some cases, is not keeping up with the faster timelines.